42 results about "Drug usage" patented technology

The present application relates to the technical field of knowledge graph, in particular to a multi-task hepatitis B drug screening method and system based on knowledge graph assistance, comprising the following steps: based on hepatitis B virus genotype sequence data recorded over time, patient drug use records and drug sensitivity. In the present application, multi-dimensional dynamic time series data such as virus genotype sequence data, patient drug use records and drug sensitivity are integrated, the interaction events between entities are marked by time stamp, the dynamic characteristics such as virus variation track and drug efficacy change are embedded in the graph node attributes, so that the knowledge representation can reflect the time dependence in the real scene. Based on biological pathway annotation information and protein interaction data, the hyperedge connection multi-entity set is defined, the limitation of traditional knowledge graph which only supports binary relationship is expanded, the drug combination and multi-target synergistic mechanism are explicitly modeled, and the misjudgment of combination effect caused by the simplification of interaction relationship is avoided.

The invention relates to the technical field of medical care data processing, and discloses a medical care data processing method and system based on artificial intelligence, and the method comprises the steps: recording a medicine taking moment, a medicine effect starting moment and a medicine effect ending moment when a user takes medicines of each dose type; executing a work intensity evaluation strategy for each time period, monitoring the typewriting frequency of the user in each time period, and calculating the work intensity of each time period according to the time period score of the user; according to historical workdays, executing a drug effect intensity matching strategy, and calculating the corresponding work intensity of the drugs of each dose category under the optimal work completion degree; executing an intelligent medicine taking time period matching strategy, and calculating the optimal medicine taking time and dosage type based on the predicted working intensity of the next workday; and a night dose intelligent back-pushing module is executed, the dose type of the medicine taken before sleep in the next workday is calculated, the matching degree between the medicine use and the work performance is improved, and the work efficiency and the state stability are maintained to the maximum extent.

The present invention relates to a gene construct and use thereof. The gene construct is used for inhibiting the excessive excitation of neurons caused by excessive use or abuse of addictive substances. The gene construct comprises a neuronal inhibitory protein-coding gene and a promoter operably linked to the neuronal inhibitory protein-coding gene. The gene construct exhibits significant advantages in terms of precise targeting, closed-loop regulation, retention of natural reward responses, reduction of side effects, and improvement of safety, as well as potential long-acting properties and sustainability. This strategy provides a novel idea and method for the treatment of drug use disorders, and is expected to become an important breakthrough in the field of drug use disorders in the future.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

The present description relates to a method for treating a patient having a mood disorder, comprising administering to a subject in need a pharmaceutical composition comprising a base compound consisting substantially of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specified dosage regimen.

A system and method for managing medication titration using real-time walking and balance data collected from mobile electronic devices are disclosed. Smartphone sensors, including accelerometers and gyroscopes, capture mobility metrics such as gait speed, stride characteristics, postural stability, and fall risk. The mobility data is integrated with additional physiological metrics and a patient's electronic medical records. Analytical algorithms, including machine-learning models, evaluate changes in mobility to identify correlations between medication usage and functional performance. Based on detected changes, the system generates alerts and recommendations to assist healthcare providers in adjusting medication dosages. The invention supports proactive and personalized medication management, particularly for medications that affect balance or fall risk, and improves patient safety by enabling data-driven clinical decision-making using real-world mobility insights.

This invention belongs to the field of drug detection, specifically relating to a method for constructing a fingerprint spectrum of Cibotium barometz and a method for determining the content of its active ingredients. The construction method includes the preparation of a test solution and detection using high-performance liquid chromatography (HPLC) to obtain the fingerprint spectrum of Cibotium barometz. This invention establishes a comprehensive and rapid method for detecting Cibotium barometz drug preparations, which is of great significance for its comprehensive quality detection and overall quality control. The characteristic spectrum obtained by this construction method has at least 12 common characteristic peaks, a stable baseline, and good peak resolution. Furthermore, the relative retention times of each characteristic peak are calculated based on protocatechuic acid, which is beneficial for the comprehensive quality detection and overall quality control of Cibotium barometz preparations, and helps improve the safety and stability of drug use.

To provide an automatic drug intake record identification cap having the function of quickly and automatically identifying drug usage records. [Solution] The cap comprises a cap main body shell 101, a partition plate, and an identification component 103. The partition plate is provided in the center of the cap main body shell, and a transparent view window 104 is provided on the top surface of the cap main body shell, and the identification component is disposed inside the cap main body shell. The identification component includes a pressing base, an identification turntable, an interlocking drive component, and a support component. The pressing base is disposed below the partition plate, and the identification turntable is disposed above the partition plate. The support component is provided between the pressing base and the identification turntable, and the identification turntable is actively engaged with the interlocking drive component.

The invention discloses an intelligent medical record classification method and system, and relates to the technical field of text classification, medical record data in unit time is collected from a hospital database, the medical record data is stored in a standardized mode, and the medical record data comprises basic information of patients, medical record details and medicine use records; performing feature entity analysis on the medical record data by using a RoBERTa-Med model to generate first data; performing feature matrix calculation on the first data based on multi-method feature selection to generate emergency priority, and performing priority ranking on the medical record data according to the emergency priority; a medical record quality control algorithm is used for matching similarity retrieval of current medical record data and historical medical record data, similar medical record data is obtained, historical similar medical records are rapidly matched for current high-risk medical records, and diagnosis and treatment scheme reference and historical result analogy are provided for doctors.

Systems, methods, and computer-readable media are disclosed for predicting heart disease events using multimodal biometric and clinical data processed by a temporally-aware machine learning model. Biometric data, such as sensor measurements and additional wearable-derived activity and physiological signals, are collected from a user over a multi-day collection time period (e.g., 10–30 days). Biometric features generated from the collected data are supplemented with clinical features such as demographic and drug-use information. The combined feature set is provided to a machine learning model comprising a sequence of transformer blocks configured to generate progressively lower-resolution temporal representations through pooling and to enforce temporal causality via causal self-attention. The model produces an output predictive of a heart disease event, which may include a metric of VO2 regression or other indicators of cardiopulmonary decline.

The invention provides an artificial intelligence anesthesia auxiliary method and system applied to a closed environment. The method comprises the following steps: S1, carrying out data acquisition; s2, setting an automatic anesthesia problem; and S3, carrying out constraint improvement on the automatic anesthesia algorithm. According to the intelligent anesthesia assisting method based on extended Actor-Critic and fusing environmental perception, stable and automatic control over the anesthesia depth can be achieved under the closed and large environmental fluctuation conditions, and compared with a conventional reinforcement learning strategy and a traditional rule control strategy which do not consider environmental factors, the intelligent anesthesia assisting method based on extended Actor-Critic and fusing environmental perception has the advantages that the intelligent anesthesia assisting method is simple and convenient to operate. The method has obvious advantages in the aspects of MAP control precision, environment disturbance adaptive capacity and drug use efficiency.

This invention provides an automatic early warning system for abnormal drug sales, comprising: a data management module for periodically collecting and processing patient business data to obtain an underlying data pool; a manual control module for selecting control objects, configuring drug sales early warning rules, determining whether the control objects meet the early warning conditions, and automatically sending early warning information if the determination result is yes; a sales anomaly judgment module for extracting abnormal data from the underlying data pool, constructing a sales anomaly prediction model, and performing real-time drug sales monitoring to obtain sales anomaly trends; and a sales prediction module for extracting sales influencing factors from the underlying data pool, constructing a sales prediction model, and performing real-time drug sales prediction to obtain predicted purchase volume and predicted purchase timing. This invention can effectively identify abnormal drug sales trends, predict drug sales trends, achieve personalized automatic early warning for abnormal drug sales, monitor drug usage and consumption, and promptly detect and respond to drugs with abnormal sales.

The application discloses application of methylphenidate in preparation of a post-traumatic stress disorder (PTSD) psychotherapy enhancer. The methylphenidate is used in the introduction period of PTSD psychotherapy, and can improve the treatment effect of core symptoms of PTSD, including intrusive symptoms, avoidance symptoms, high vigilance symptoms, negative thinking and emotion. The application uses single methylphenidate to disturb patients into an unstable state, adjusts a time window for reconsolidation of trauma memory, and strengthens the decline of trauma memory and the update of healing memory in the time window. Furthermore, compared with daily medication, single medication has clinical significance of reducing the psychological burden and economic burden of patients on drug use. Therefore, the application uses single methylphenidate in the introduction period of PTSD psychotherapy.

The invention discloses an individualized infection control decision-making system based on wound surface microecology and a data processing method, the system collects a local sample of a wound surface, obtains a 16SrDNA or metagenome sequencing result, conventional etiology, inflammation indexes and patient conditions, and records plant defensin BKX-1 and antibacterial drug administration information; the micro-ecological and clinical features are subjected to fusion modeling based on machine learning, a wound infection severity score and a drug resistance risk score are output, an individualized infection control scheme is generated in combination with a preset antibacterial drug use rule, BKX-1 local drug use is preferentially recommended when the risk is low, broad-spectrum antibacterial drugs are reduced, and the risk is reduced. When the risk is high, etiology inspection and medication upgrading are prompted; and data of multiple patients can be counted to form quality indexes such as etiology inspection rate and the like. The method is beneficial to improving the etiology inspection rate, optimizing the use of antibacterial drugs and promoting wound infection control.

The invention provides a transdermal analgesic patch as well as a preparation method and application thereof. The transdermal analgesic patch consists of a polyethylene glycol terephthalate backing layer, a drug-containing gel layer and a silicified polyester anti-sticking layer. The medicine-containing gel layer takes diclofenac sodium, menthol and capsaicin as analgesic active ingredients according to a specific proportion, and raw materials such as a laurocapram and L-menthol compound penetration enhancer, a blending pressure-sensitive adhesive matrix and a compound antioxidant are matched. The preparation method comprises the steps of dissolving, mixing, coating, drying, compounding and the like, and the process is mild and controllable. The patch is excellent in transdermal performance, the steady-state transdermal rate reaches up to 38.3 micrograms / cm < 2 > h, the 24-hour analgesic total effective rate is 93.3%, and the patch is good in stability and free of layering and curling problems. The traditional Chinese medicine composition can be used for preparing medicines for treating postoperative acute pain or chronic neuropathic pain, and is convenient to use and stable in effect.

The invention discloses a drug sensitivity test drug recommendation system, method and device based on an AI large model and a medium, relates to the technical field of drug sensitivity tests, is applied to a computer device, and comprises a medical object information collection module used for collecting medical feature information from initial medical information of a medical object by using a feature information extraction AI large model; the medical feature information comprises basic information of a medical object, current and past drug allergy information and disease information; the drug recommendation module is used for determining a preliminary drug recommendation result according to a drug sensitive test result of the medical object and a preset expert database constructed based on a drug use industry standard; the medication recommendation module is used for inputting the medical feature information, the preliminary medication recommendation result and a medication database into a medication recommendation AI large model and outputting a target medication recommendation conclusion; the target drug use recommendation conclusion at least comprises recommended drugs, drug use risk information of the recommended drugs and drug use details. And more accurate and practical drug recommendation is realized.

The invention relates generally to medication therapy and more particularly to a system and methods for medication therapy management to support improved adherence and alert clinicians of changes in behavior or symptoms. The system may facilitate interactions between various data sources (e.g., medical health records, genomics databases, and other connected third-party devices) to manage workflow, execute rules, interface with knowledge bases, codify information, schedule events, provide notification, and more. In addition, the system may include a conversational or actionable artificial intelligence persona tailored to each user and configured to, for example, converse, instruct, and / or coach a user according to one or more features of the system. Advantageously, the system may improve adherence and facilitate patient engagement, care transition, and disease management, resulting in, for example, reduced healthcare costs for providers and payers, and enhanced drug use for pharmaceutical manufacturers, pharmacies, and specialty pharmacies.

The invention provides a soluble microneedle loaded with triptolide and salvianolic acid A as well as a preparation method and application of the soluble microneedle, and relates to the technical field of pharmaceutical preparations. According to the invention, the soluble microneedle is utilized to load the triptolide nanocrystal and the salvianolic acid A, and the medicine which can directly act on the diseased joint of a patient with rheumatoid arthritis through local transdermal administration is prepared. By using the soluble microneedle loaded with the triptolide and the salvianolic acid A, the skin delivery capacity can be improved, accumulation of diseased regions is increased, meanwhile, side effects caused by systemic drug absorption are reduced, the curative effect is improved by using the two drugs together, and the soluble microneedle loaded with the triptolide and the salvianolic acid A has a better treatment effect on rheumatoid arthritis.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The invention relates to the technical field of medical spraying device control, and discloses a tetracaine spraying can spraying pressure closed-loop control method and device. According to the device, negative pressure spherical variable state parameters and liquid medicine flow resistance parameters are obtained, the actual injection pressure is calculated based on the pressure-deformation mapping relation, the actual injection pressure is compared with a target pressure range, then a regulation and control instruction is generated, an operator is guided to adjust the holding force, feedback information is collected, a mapping coefficient is updated, and closed-loop pressure control is achieved. The injection pressure distribution can be accurately controlled, the medicine using efficiency is improved, medicine waste is reduced, and it is ensured that the injection dosage is uniform and stable.

The present disclosure relates to a method of treating a patient having a mood disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a base compound comprising substantially pure N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specific dosing regimen.

The application discloses a kind of coronary artery CT imaging review time window prediction methods of fusion multi-source information, comprising: collecting patient multidimensional data, based on multidimensional data confirmation imaging index, based on multidimensional data collation baseline clinical information and collation patient's drug use, secondly induction coronary heart disease patient's CCTA review time, construct multidimensional data set, data set is preprocessed, risk factor is assigned quantization;Through the data constructed after processing LightGBM submodel, the accuracy and generalization ability of final prediction result are improved using Stacking method, the loss function is reduced by introducing model-independent local interpretable technology LIME;Through the above method, the current evaluation method only includes traditional factors such as hypertension and diabetes, ignores the imaging information and rich clinical information in electronic medical record which can be directly quantified and represent individualized plaque characteristics and the interaction between multi-source information, so that it is difficult to accurately predict the best CCTA review time window.

The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. 50 The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves the technical problem of drug resistance in the use process of existing platinum drugs. The application discloses an 8-hydroxyquinoline-N-oxide zinc complex and a preparation method thereof, and belongs to the technical field of medicines, and solves

Systems and methods are provided for establishing an expected benefit of medication use from a patient. A neural network is trained on a dataset of medical images, such as ultrasound images, tagged with information relating to an expected benefit of a medicament for a person imaged to produce the medical image. A medical image of the patient may then be provided to the trained neural network, and the neural network may then be determined regarding an expected benefit of medication usage from the patient.

A medication use support system including a communication device provided to a medicine and a terminal that stores and manages medication information, wherein the terminal includes: a reading unit which reads first trigger information for acquiring information of the medicine; a communication unit which performs wireless communication with the communication device; a storage unit which stores management information of the medicine; a display unit which displays a medication use management screen including the management information of the medicine; and a control unit which determines a use status of the medicine by communication with the communication device, the communication device is in a communicable state with the terminal when not shielded by the electromagnetic wave shielding member and transmits second trigger information to the communication unit in the communicable state.

The application discloses a cardiovascular disease drug recommendation method and system based on Spark, wherein the cardiovascular disease drug recommendation system is provided with a drug information collection module, a user demand determination module, a data screening module, a target extraction module, a combination recommendation module and a user server; the data screening module screens out recommended cardiovascular disease drugs according to a demand determination benchmark and performs sorting; and the combination recommendation module screens out associated purchase drugs according to the use conditions of the associated drugs of the corresponding recommended cardiovascular disease drugs and performs sorting. The user demand determination module and the data screening module are used to obtain a drug sorting list meeting the requirements of demanders, so that the drug selection efficiency is improved, and the drug selection pertinence and accuracy are improved; in addition, the combination recommendation module is used to screen out the associated purchase drugs and perform sorting, so that the demanders can obtain the associated purchase drugs with the best combination treatment effect and select the associated purchase drugs, and the drug selection accuracy is further improved.

The invention belongs to the technical field of medicines, and particularly relates to application of 4-octyl itaconic acid in preparation of a medicine for preventing and / or treating depression, and application of pharmaceutically acceptable salt of the 4-octyl itaconic acid or a 4-octyl itaconic acid derivative in preparation of the medicine for preventing and / or treating depression. The invention proves that the 4-octyl itaconic acid has obvious prevention and improvement effects on depression. In addition, as the 4-octyl itaconic acid naturally exists in metabolites of immune cells such as macrophages, the 4-octyl itaconic acid also has very high safety when being used as a medicine. Therefore, the 4-octyl itaconic acid can be used for preparing the medicine for preventing and / or treating the depression and has a very good application prospect.

The utility model discloses a silent packaging bottle for quantitatively taking medicine, and belongs to the technical field of medicine packaging. In order to solve the technical problems of quantitative medicine taking and portable storage, a multi-layer medicine storage structure, a limiting and fixing design and a mute packaging technology are mainly adopted. The portable medicine taking box can achieve quantitative medicine taking, sealed medicine storage and portability, reduces noise interference in the carrying process, effectively improves safety and convenience of medicine use, is suitable for patients suffering from hypertension, heart diseases and diabetes and special groups to take medicine on time according to the dosage, meanwhile protects the surfaces of the medicine, and prolongs the stability of the medicine effect.